Commercialization Challenges for Gene and Cell Therapies

Thought Leader:

Roshawn Blunt, Managing Director, 1798, a Fingerpaint company

October 8, 2020      

Roshawn Blunt, 1798, a Fingerpaint company, talks about the unique commercialization challenges gene and cell therapy companies face with Taren Grom from PharmaVOICE.

Post a Comment

You must be logged in to post a Comment.